FDA Advisory Committee Gives Thumbs Up to Gattex in SBS
By Catherine Shaffer
Wednesday, October 17, 2012
The FDA's Gastrointestinal Drugs Advisory Committee (GIDAC) voted unanimously Tuesday that the benefits of NPS Pharmaceuticals Inc.'s Gattex (teduglutide) for short bowel syndrome (SBS) outweighed its risks, and that the drug should be approved.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.